Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Author:

Saiag Philippe,Robert Caroline,Grob Jean-Jacques,Mortier Laurent,Dereure Olivier,Lebbe Céleste,Mansard Sandrine,Grange Florent,Neidhardt Eve-Marie,Lesimple Thierry,Machet Laurent,Bedane Christophe,Maillard Hervé,Dalac-Rat Sophie,Nardin Charlée,Szenik Alexandra,Denden Amine,Dutriaux Caroline

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018. Overview;Defossez,2019

2. ©Plateformes hospitalières de génétique moléculaire des cancers: faits marquants et synthèse d’activité 2013,2014

3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

5. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors;Su;N Engl J Med,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3